Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Clin Cancer Res. 2000 Jul;6(7):2702-6.
The present study was undertaken to evaluate the prognostic significance of the serum levels of interleukin 6 (IL-6) in patients with prostate cancer. Serum IL-6 levels were measured in 74 patients with prostate cancer. The tumor was stage B in 23 patients, stage C in 14 patients, and stage D in 37 patients. Prognostic significance of tumor histology, performance status (PS), bone metastasis, serum prostate-specific antigen (PSA) level, serum alkaline phosphatase (ALP) level, serum lactate dehydrogenase level, serum IL-6 levels, and hemoglobin on disease-specific survival was assessed using univariate and multivariate Cox's proportional hazards model analyses. Serum IL-6 was significantly correlated with the clinical stage of prostate cancer. Univariate analysis of all patients demonstrated that an extent of disease (EOD) on bone scanning > or = 1, IL-6 > or = 7 pg/ml, PS > or = 1, PSA > 100 ng/ml, and ALP > 620 IU/liter were associated with a significantly lower survival rate than their respective counterparts. In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. In 51 patients with stage C and stage D prostate cancer, univariate analysis showed that EOD > or = 1, IL-6 > or = 7 pg/ml, PS > or = 1, PSA > 100 ng/ml, LDH > 200 IU/liter, and ALP > 620 IU/liter were significantly related to survival, whereas multivariate analysis again demonstrated that EOD > or = 1 and IL-6 > or = 7 pg/ml were significant prognostic factors. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD.
本研究旨在评估前列腺癌患者血清白细胞介素6（IL-6）水平的预后意义。对74例前列腺癌患者测定了血清IL-6水平。其中23例患者肿瘤为B期，14例为C期，37例为D期。采用单因素和多因素Cox比例风险模型分析评估肿瘤组织学、体能状态（PS）、骨转移、血清前列腺特异性抗原（PSA）水平、血清碱性磷酸酶（ALP）水平、血清乳酸脱氢酶水平、血清IL-6水平及血红蛋白对疾病特异性生存的预后意义。血清IL-6与前列腺癌的临床分期显著相关。对所有患者的单因素分析表明，骨扫描显示疾病范围（EOD）≥1、IL-6≥7 pg/ml、PS≥1、PSA>100 ng/ml及ALP>620 IU/L的患者生存率显著低于各自的对照值。然而，多因素分析显示，仅有的两个显著预后因素为EOD和IL-6。在51例C期和D期前列腺癌患者中，单因素分析显示EOD≥1、IL-6≥7 pg/ml、PS≥1、PSA>100 ng/ml、LDH>200 IU/L及ALP>620 IU/L与生存显著相关，而多因素分析再次表明EOD≥1和IL-6≥7 pg/ml是显著预后因素。这些结果表明，血清IL-6水平以及EOD是前列腺癌的显著预后因素。
